Search

Your search keyword '"Advani, Ranjana"' showing total 20 results
Start Over Author "Advani, Ranjana" Database OAIster
20 results on '"Advani, Ranjana"'

1. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

Author

Prince, H. Miles, Hutchings, Martin, Domingo-Domenech, Eva, Eichenauer, Dennis A., Advani, Ranjana, Prince, H. Miles, Hutchings, Martin, Domingo-Domenech, Eva, Eichenauer, Dennis A., and Advani, Ranjana

Abstract

CD30 is overexpressed in several lymphoma types, including classic Hodgkin lymphoma (cHL), some peripheral T-cell lymphomas (PTCL), and some cutaneous T-cell lymphomas. The antibody-drug conjugate brentuximab vedotin targets CD30-positive cells and has been evaluated for the treatment of various lymphoma entities. This narrative review summarizes 10 years of experience with brentuximab vedotin for the treatment of CD30-positive lymphomas, discusses novel therapies targeting CD30 in development, and highlights remaining controversies relating to CD30-targeted therapy across lymphoma types. The collective body of evidence for brentuximab vedotin demonstrates that exploitation of CD30 can provide sustained benefits across a range of different CD30-positive lymphomas, in both clinical trials and real-world settings. Preliminary experience with brentuximab vedotin in combination with immune checkpoint inhibitors for relapsed/refractory cHL is encouraging, but further exploration is required. The optimal use of brentuximab vedotin for first-line therapy of PTCL remains to be determined. Further research is required on brentuximab vedotin treatment in high-risk patient populations, and in rare lymphoma subtypes, for which no standard of care exists. Novel therapies targeting CD30 include chimeric antigen receptor therapies and bispecific antibody T-cell engagers, which may be expected to further improve outcomes for patients with CD30-positive lymphomas in the coming years.

Published
2023

2. Role of Stem Cell Transplant in CD30+ PTCL Following Frontline Brentuximab Vedotin Plus CHP or CHOP in ECHELON-2.

Author

Savage, Kerry J, Horwitz, Steven M, Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O'Connor, Owen A, Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, Iyer, Swaminathan, Savage, Kerry J, Horwitz, Steven M, Advani, Ranjana, Christensen, Jacob Haaber, Domingo-Domenech, Eva, Rossi, Giuseppe, Morschhauser, Franck, Alpdogan, Onder, Suh, Cheolwon, Tobinai, Kensei, Shustov, Andrei, Trneny, Marek, Yuen, Sam, Zinzani, Pier Luigi, Trümper, Lorenz, Ilidge, Tim, O'Connor, Owen A, Pro, Barbara, Miao, Harry, Bunn, Veronica, Fenton, Keenan, Fanale, Michelle, Puhlmann, Markus, and Iyer, Swaminathan

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have high relapse rates following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy, there remains no consensus on its utility. The double-blind randomized phase 3 ECHELON-2 study (#NCT01777152; clinicaltrials.gov) demonstrated improved progression-free survival (PFS) and overall survival with frontline brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A+CHP). Herein, we conducted an exploratory subgroups analysis of the impact of consolidative SCT on PFS in patients with previously untreated CD30+ PTCL (ALK- anaplastic large cell lymphoma [ALCL] and non-ALCL) who were in complete response (CR) after frontline treatment with A+CHP or cyclophosphamide, doxorubicin, vincristine, and prednisone. Median PFS follow-up was 47.57 months. The PFS hazard ratio was 0.36, equating to a 64% reduction in the risk of a PFS event in patients who underwent SCT. The median PFS in patients who underwent SCT was not reached, vs 55.66 months in patients who did not undergo SCT. PFS results favored the use of SCT in both ALK- ALCL and non-ALCL subgroups. These data support the consideration of consolidative SCT in patients with CD30+PTCL who achieve CR following treatment with A+CHP.

Published
2022

3. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma:A multi-institutional study of adult patients by ILROG

Author

Binkley, Michael S., Shahzad Rauf, M., Milgrom, Sarah A., Pinnix, Chelsea C., Tsang, Richard, Dickinson, Michael, Ng, Andrea K., Roberts, Kenneth B., Gao, Sarah, Balogh, Alex, Ricardi, Umberto, Levis, Mario, Casulo, Carla, Stolten, Michael, Specht, Lena, Plastaras, John P., Wright, Christopher, Kelsey, Christopher R., Brady, Jessica L., George Mikhaeel, N., Hoppe, Bradford S., Terezakis, Stephanie A., Picardi, Marco, Pepa, Roberta Della, Kirova, Youlia, Akhtar, Saad, Maghfoor, Irfan, Koenig, Julie L., Jackson, Christopher, Song, Erin, Sehgal, Shuchi, Advani, Ranjana H., Natkunam, Yasodha, Constine, Louis S., Eich, Hans T., Wirth, Andrew, Hoppe, Richard T., Binkley, Michael S., Shahzad Rauf, M., Milgrom, Sarah A., Pinnix, Chelsea C., Tsang, Richard, Dickinson, Michael, Ng, Andrea K., Roberts, Kenneth B., Gao, Sarah, Balogh, Alex, Ricardi, Umberto, Levis, Mario, Casulo, Carla, Stolten, Michael, Specht, Lena, Plastaras, John P., Wright, Christopher, Kelsey, Christopher R., Brady, Jessica L., George Mikhaeel, N., Hoppe, Bradford S., Terezakis, Stephanie A., Picardi, Marco, Pepa, Roberta Della, Kirova, Youlia, Akhtar, Saad, Maghfoor, Irfan, Koenig, Julie L., Jackson, Christopher, Song, Erin, Sehgal, Shuchi, Advani, Ranjana H., Natkunam, Yasodha, Constine, Louis S., Eich, Hans T., Wirth, Andrew, and Hoppe, Richard T.

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ‡16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT1chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n 5 257; 46.0%), CMT (n 5 184; 32.9%), CT alone (n 5 47; 8.4%), observation (n 5 37; 6.6%), rituximab and RT (n 5 19; 3.4%), and rituximab alone (n 5 15; 2.7%). The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites >2 were associated with worse PFS (P <.05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly higher transformation rate in those with variant immunoarchitectural pattern (P 5.049) and number of involved sites >2 (P 5.0006). OS for patients with stage I-II NLPHL was excellent after all treatments.

Published
2020

4. DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

Author

Vrabac, Damir, Smit, Akshay, Rojansky, Rebecca, Natkunam, Yasodha, Advani, Ranjana H., Ng, Andrew Y., Fernandez-Pol, Sebastian, Rajpurkar, Pranav, Vrabac, Damir, Smit, Akshay, Rojansky, Rebecca, Natkunam, Yasodha, Advani, Ranjana H., Ng, Andrew Y., Fernandez-Pol, Sebastian, and Rajpurkar, Pranav

Abstract

Diffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Though histologically DLBCL shows varying morphologies, no morphologic features have been consistently demonstrated to correlate with prognosis. We present a morphologic analysis of histology sections from 209 DLBCL cases with associated clinical and cytogenetic data. Duplicate tissue core sections were arranged in tissue microarrays (TMAs), and replicate sections were stained with H&E and immunohistochemical stains for CD10, BCL6, MUM1, BCL2, and MYC. The TMAs are accompanied by pathologist-annotated regions-of-interest (ROIs) that identify areas of tissue representative of DLBCL. We used a deep learning model to segment all tumor nuclei in the ROIs, and computed several geometric features for each segmented nucleus. We fit a Cox proportional hazards model to demonstrate the utility of these geometric features in predicting survival outcome, and found that it achieved a C-index (95% CI) of 0.635 (0.574,0.691). Our finding suggests that geometric features computed from tumor nuclei are of prognostic importance, and should be validated in prospective studies., Comment: Corrections to folder structure figure

Published
2020

5. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma:A multi-institutional study of adult patients by ILROG

Author

Binkley, Michael S., Shahzad Rauf, M., Milgrom, Sarah A., Pinnix, Chelsea C., Tsang, Richard, Dickinson, Michael, Ng, Andrea K., Roberts, Kenneth B., Gao, Sarah, Balogh, Alex, Ricardi, Umberto, Levis, Mario, Casulo, Carla, Stolten, Michael, Specht, Lena, Plastaras, John P., Wright, Christopher, Kelsey, Christopher R., Brady, Jessica L., George Mikhaeel, N., Hoppe, Bradford S., Terezakis, Stephanie A., Picardi, Marco, Pepa, Roberta Della, Kirova, Youlia, Akhtar, Saad, Maghfoor, Irfan, Koenig, Julie L., Jackson, Christopher, Song, Erin, Sehgal, Shuchi, Advani, Ranjana H., Natkunam, Yasodha, Constine, Louis S., Eich, Hans T., Wirth, Andrew, Hoppe, Richard T., Binkley, Michael S., Shahzad Rauf, M., Milgrom, Sarah A., Pinnix, Chelsea C., Tsang, Richard, Dickinson, Michael, Ng, Andrea K., Roberts, Kenneth B., Gao, Sarah, Balogh, Alex, Ricardi, Umberto, Levis, Mario, Casulo, Carla, Stolten, Michael, Specht, Lena, Plastaras, John P., Wright, Christopher, Kelsey, Christopher R., Brady, Jessica L., George Mikhaeel, N., Hoppe, Bradford S., Terezakis, Stephanie A., Picardi, Marco, Pepa, Roberta Della, Kirova, Youlia, Akhtar, Saad, Maghfoor, Irfan, Koenig, Julie L., Jackson, Christopher, Song, Erin, Sehgal, Shuchi, Advani, Ranjana H., Natkunam, Yasodha, Constine, Louis S., Eich, Hans T., Wirth, Andrew, and Hoppe, Richard T.

Abstract

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon histologic variant, and the optimal treatment of stage I-II NLPHL is undefined. We conducted a multicenter retrospective study including patients ‡16 years of age with stage I-II NLPHL diagnosed from 1995 through 2018 who underwent all forms of management, including radiotherapy (RT), combined modality therapy (CMT; RT1chemotherapy [CT]), CT, observation after excision, rituximab and RT, and single-agent rituximab. End points were progression-free survival (PFS), freedom from transformation, and overall survival (OS) without statistical comparison between management groups. We identified 559 patients with median age of 39 years: 72.3% were men, and 54.9% had stage I disease. Median follow-up was 5.5 years (interquartile range, 3.1-10.1). Five-year PFS and OS in the entire cohort were 87.1% and 98.3%, respectively. Primary management was RT alone (n 5 257; 46.0%), CMT (n 5 184; 32.9%), CT alone (n 5 47; 8.4%), observation (n 5 37; 6.6%), rituximab and RT (n 5 19; 3.4%), and rituximab alone (n 5 15; 2.7%). The 5-year PFS rates were 91.1% after RT, 90.5% after CMT, 77.8% after CT, 73.5% after observation, 80.8% after rituximab and RT, and 38.5% after rituximab alone. In the RT cohort, but not the CMT cohort, variant immunoarchitectural pattern and number of sites >2 were associated with worse PFS (P <.05). Overall, 21 patients (3.8%) developed large-cell transformation, with a significantly higher transformation rate in those with variant immunoarchitectural pattern (P 5.049) and number of involved sites >2 (P 5.0006). OS for patients with stage I-II NLPHL was excellent after all treatments.

Published
2020

6. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Castillo, Jorge J, Advani, Ranjana H, Branagan, Andrew R, Buske, Christian, Dimopoulos, Meletios A, D'Sa, Shirley, Kersten, Marie José, Leblond, Veronique, Minnema, Monique C, Owen, Roger G, Palomba, M Lia, Talaulikar, Dipti, Tedeschi, Alessandra, Trotman, Judith, Varettoni, Marzia, Vos, Josephine M, Treon, Steven P, Kastritis, Efstathios, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Castillo, Jorge J, Advani, Ranjana H, Branagan, Andrew R, Buske, Christian, Dimopoulos, Meletios A, D'Sa, Shirley, Kersten, Marie José, Leblond, Veronique, Minnema, Monique C, Owen, Roger G, Palomba, M Lia, Talaulikar, Dipti, Tedeschi, Alessandra, Trotman, Judith, Varettoni, Marzia, Vos, Josephine M, Treon, Steven P, and Kastritis, Efstathios

Published
2020

7. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Talaulikar, Dipti, Advani, Ranjana H, Branagan, Andrew R, Buske, Christian, Dimopoulos, Meletios A, D'Sa, Shirley, Kersten, Maria J, Leblond, Veronique, Minnema, Monique C, Owen, Roger G, Palomba, Maria Lia, Tedeschi, Alessandra, Trotman, Judith, Varettoni, Marzia, Vos, Josephine M, Treon, Steven P, Kastritis, Efstathios, Castillo, Jorge J, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Talaulikar, Dipti, Advani, Ranjana H, Branagan, Andrew R, Buske, Christian, Dimopoulos, Meletios A, D'Sa, Shirley, Kersten, Maria J, Leblond, Veronique, Minnema, Monique C, Owen, Roger G, Palomba, Maria Lia, Tedeschi, Alessandra, Trotman, Judith, Varettoni, Marzia, Vos, Josephine M, Treon, Steven P, Kastritis, Efstathios, and Castillo, Jorge J

Published
2020

8. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.

Author

Advani, Ranjana, Advani, Ranjana, Hong, Fangxin, Fisher, Richard, Bartlett, Nancy, Robinson, K, Gascoyne, Randy, Wagner, Henry, Stiff, Patrick, Cheson, Bruce, Stewart, Douglas, Gordon, Leo, Kahl, Brad, Friedberg, Jonathan, Blum, Kristie, Habermann, Thomas, Tuscano, Joseph, Hoppe, Richard, Horning, Sandra, Advani, Ranjana, Advani, Ranjana, Hong, Fangxin, Fisher, Richard, Bartlett, Nancy, Robinson, K, Gascoyne, Randy, Wagner, Henry, Stiff, Patrick, Cheson, Bruce, Stewart, Douglas, Gordon, Leo, Kahl, Brad, Friedberg, Jonathan, Blum, Kristie, Habermann, Thomas, Tuscano, Joseph, Hoppe, Richard, and Horning, Sandra

Abstract

PURPOSE: The phase III North American Intergroup E2496 Trial (Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkins Lymphoma) compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine, doxorubicin, vincristine, bleomycin, vinblastine, etoposide, and prednisone (Stanford V). We report results of a planned subgroup analysis in patients with stage I or II bulky mediastinal Hodgkin lymphoma (HL). PATIENTS AND METHODS: Patients were randomly assigned to six to eight cycles of ABVD every 28 days or Stanford V once per week for 12 weeks. Two to 3 weeks after completion of chemotherapy, all patients received 36 Gy of modified involved field radiotherapy (IFRT) to the mediastinum, hila, and supraclavicular regions. Patients on the Stanford V arm received IFRT to additional sites ≥ 5 cm at diagnosis. Primary end points were failure-free survival (FFS) and overall survival (OS). RESULTS: Of 794 eligible patients, 264 had stage I or II bulky disease, 135 received ABVD, and 129 received Stanford V. Patient characteristics were matched. The overall response rate was 83% with ABVD and 88% with Stanford V. At a median follow-up of 6.5 years, the study excluded a difference of more than 21% in 5-year FFS and more than 16% in 5-year OS between ABVD and Stanford V (5-year FFS: 85% v 79%; HR, 0.68; 95% CI, 0.37 to 1.25; P = .22; 5-year OS: 96% v 92%; HR, 0.49; 95% CI, 0.16 to 1.47; P = .19). In-field relapses occurred in < 10% of the patients in each arm. CONCLUSION: For patients with stage I or II bulky mediastinal HL, no substantial statistically significant differences were detected between the two regimens, although power was limited. To the best of our knowledge, this is the first prospective trial reporting outcomes specific to this subgroup, and it sets a benchmark for comparison of ongoing and future studies.

Published
2015

9. The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma:Guidelines From the International Lymphoma Radiation Oncology Group

Author

Constine, Louis S, Yahalom, Joachim, Ng, Andrea K, Hodgson, David C, Wirth, Andrew, Milgrom, Sarah A, Mikhaeel, N George, Eich, Hans Theodor, Illidge, Tim, Ricardi, Umberto, Dieckmann, Karin, Moskowitz, Craig H, Advani, Ranjana, Mauch, Peter M, Specht, Lena, Hoppe, Richard T, Constine, Louis S, Yahalom, Joachim, Ng, Andrea K, Hodgson, David C, Wirth, Andrew, Milgrom, Sarah A, Mikhaeel, N George, Eich, Hans Theodor, Illidge, Tim, Ricardi, Umberto, Dieckmann, Karin, Moskowitz, Craig H, Advani, Ranjana, Mauch, Peter M, Specht, Lena, and Hoppe, Richard T

Abstract

Relapsed and refractory Hodgkin lymphoma (HL) challenges clinicians to devise treatment strategies that are effective and safe. This problem is particularly prominent in an era when de-escalation trials are designed to minimize therapeutic toxicities in both early- and advanced-stage disease. Radiation therapy is the single most effective treatment modality for HL, and its integration into salvage regimens, or its independent use in select patients, must be understood to maximize our success in treating these patients. The complexity of treating relapsed or refractory HL derives from the spectrum of primary treatment approaches currently in use that creates heterogeneity in both treatment exposure and the potential toxicities of salvage therapy. Patients can have relapsed or refractory disease after limited or aggressive primary therapy (with or without radiation therapy), at early or delayed time points, with limited or extensive disease volumes, and with varying degrees of residual morbidity from primary therapy. Their response to salvage systemic therapy can be partial or complete, and the use of consolidative stem cell transplantation is variably applied. New biologics and immunotherapeutic approaches have broadened but also complicated salvage treatment approaches. Through all of this, radiation therapy remains an integral component of treatment for many patients, but it must be used effectively and judiciously. The purpose of this review is to describe the different treatment scenarios and provide guidance for radiation dose, volume, and timing in patients with relapsed or refractory HL.

Published
2018

10. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Author

Tao, Li, Tao, Li, Clarke, Christina A, Rosenberg, Aaron S, Advani, Ranjana H, Jonas, Brian A, Flowers, Christopher R, Keegan, Theresa HM, Tao, Li, Tao, Li, Clarke, Christina A, Rosenberg, Aaron S, Advani, Ranjana H, Jonas, Brian A, Flowers, Christopher R, and Keegan, Theresa HM

Abstract

With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for SPMs among 23 879 patients who survived at least 1 year after a first primary DLBCL diagnosed during 1989-2012, compared to the general population in California. Cumulative incidence (CMI) of SPMs, accounting for the competing risk of death, also was calculated. We found that the incidence of acute myeloid leukaemia (AML) nearly doubled in the post-rituximab era [SIR (95% CI) 4·39 (2·51-7·13) pre- (1989-2000) and 8·70 (6·62-11·22) post-rituximab (2001-2012)]. Subsequent thyroid cancer was rare pre-rituximab, but increased substantially after 2001 [0·66 (0·08-2·37) vs. 2·27(1·44-3·41)]. The 5-year CMI for all SPMs (4·77% pre- vs. 5·41% post-rituximab, P = 0·047), AML (0·15% vs. 0·41%, P = 0·003), thyroid cancer (0·03% vs. 0·15%, P = 0·003) and melanoma (0·25% vs. 0·42%, P = 0·020) were greater in DLBCL patients diagnosed in the post- versus pre-rituximab period. This study provides insight into the changing pattern of SPM occurrence after the introduction of rituximab, which may elucidate the aetiology of SPMs and should guide future cancer surveillance efforts among DLBCL patients.

Published
2017

11. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

Author

Tao, Li, Tao, Li, Clarke, Christina A, Rosenberg, Aaron S, Advani, Ranjana H, Jonas, Brian A, Flowers, Christopher R, Keegan, Theresa HM, Tao, Li, Tao, Li, Clarke, Christina A, Rosenberg, Aaron S, Advani, Ranjana H, Jonas, Brian A, Flowers, Christopher R, and Keegan, Theresa HM

Abstract

With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for SPMs among 23 879 patients who survived at least 1 year after a first primary DLBCL diagnosed during 1989-2012, compared to the general population in California. Cumulative incidence (CMI) of SPMs, accounting for the competing risk of death, also was calculated. We found that the incidence of acute myeloid leukaemia (AML) nearly doubled in the post-rituximab era [SIR (95% CI) 4·39 (2·51-7·13) pre- (1989-2000) and 8·70 (6·62-11·22) post-rituximab (2001-2012)]. Subsequent thyroid cancer was rare pre-rituximab, but increased substantially after 2001 [0·66 (0·08-2·37) vs. 2·27(1·44-3·41)]. The 5-year CMI for all SPMs (4·77% pre- vs. 5·41% post-rituximab, P = 0·047), AML (0·15% vs. 0·41%, P = 0·003), thyroid cancer (0·03% vs. 0·15%, P = 0·003) and melanoma (0·25% vs. 0·42%, P = 0·020) were greater in DLBCL patients diagnosed in the post- versus pre-rituximab period. This study provides insight into the changing pattern of SPM occurrence after the introduction of rituximab, which may elucidate the aetiology of SPMs and should guide future cancer surveillance efforts among DLBCL patients.

Published
2017

12. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Author

Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, Dimopoulos, Meletios A, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, and Dimopoulos, Meletios A

Published
2016

13. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Author

Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, Dimopoulos, Meletios A, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, and Dimopoulos, Meletios A

Published
2016

14. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Author

Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, Dimopoulos, Meletios A, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, and Dimopoulos, Meletios A

Published
2016

15. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Infection & Immunity, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, Dimopoulos, Meletios A, MS Hematologie, Regenerative Medicine and Stem Cells, Infection & Immunity, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, and Dimopoulos, Meletios A

Published
2016

16. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, Steensma, David P, Tefferi, Ayalew, Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Published
2015

17. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, Steensma, David P, Tefferi, Ayalew, Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Published
2015

18. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Author

Diefenbach, Catherine, Diefenbach, Catherine, Li, Hailun, Hong, Fangxin, Gordon, Leo, Fisher, Richard, Bartlett, Nancy, Crump, Michael, Gascoyne, Randy, Wagner, Henry, Stiff, Patrick, Cheson, Bruce, Stewart, Douglas, Kahl, Brad, Friedberg, Jonathan, Blum, Kristie, Habermann, Thomas, Tuscano, Joseph, Hoppe, Richard, Horning, Sandra, Advani, Ranjana, Diefenbach, Catherine, Diefenbach, Catherine, Li, Hailun, Hong, Fangxin, Gordon, Leo, Fisher, Richard, Bartlett, Nancy, Crump, Michael, Gascoyne, Randy, Wagner, Henry, Stiff, Patrick, Cheson, Bruce, Stewart, Douglas, Kahl, Brad, Friedberg, Jonathan, Blum, Kristie, Habermann, Thomas, Tuscano, Joseph, Hoppe, Richard, Horning, Sandra, and Advani, Ranjana

Abstract

The International Prognostic Score (IPS-7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies suggest the IPS-7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS-7 recorded at study entry for 854 patients enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and overall survival (OS). The IPS-7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for OS. An alternative prognostic index, the IPS-3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P = 0·0001) and OS (P < 0·0001)]. IPS-3 outperformed the IPS-7 on risk prediction for both FFP and OS by model fit and discrimination criteria. Using reclassification calibration, 18% of IPS-7 low risk patients were re-classified as intermediate risk and 13% of IPS-7 intermediate risk patients as low risk. For patients with advanced HL, the IPS-3 may provide a simpler and more accurate framework for risk assessment in the modern era. Validation of these findings in other large data sets is planned.

Published
2015

19. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.

Author

Zelenetz, Andrew D, Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, Sundar, Hema, National comprehension cancer network, Zelenetz, Andrew D, Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Habermann, Thomas M, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Wilson, Lynn, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, Sundar, Hema, and National comprehension cancer network

Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

Published
2015

20. Non-Hodgkin's lymphomas, version 4.2014.

Author

Zelenetz, Andrew D, Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, Sundar, Hema, National comprehensive cancer network, Zelenetz, Andrew D, Zelenetz, Andrew D, Gordon, Leo I, Wierda, William G, Abramson, Jeremy S, Advani, Ranjana H, Andreadis, C Babis, Bartlett, Nancy, Byrd, John C, Czuczman, Myron S, Fayad, Luis E, Fisher, Richard I, Glenn, Martha J, Harris, Nancy Lee, Hoppe, Richard T, Horwitz, Steven M, Kelsey, Christopher R, Kim, Youn H, Krivacic, Susan, LaCasce, Ann S, Nademanee, Auayporn, Porcu, Pierluigi, Press, Oliver, Rabinovitch, Rachel, Reddy, Nishitha, Reid, Erin, Saad, Ayman A, Sokol, Lubomir, Swinnen, Lode J, Tsien, Christina, Vose, Julie M, Yahalom, Joachim, Zafar, Nadeem, Dwyer, Mary, Sundar, Hema, and National comprehensive cancer network

Abstract

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results